Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.8303
-0.0310 (-3.60%)
At close: May 15, 2026, 4:00 PM EDT
0.8613
+0.0310 (3.73%)
After-hours: May 15, 2026, 7:59 PM EDT
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or -18.75% compared to the previous year.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,286,634
Market Cap
8.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 15 | -6 | -28.57% | 15 | 0 |
| Mar 31, 2025 | 15 | -11 | -42.31% | 15 | 0 |
| Dec 31, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Sep 30, 2024 | 19 | -12 | -38.71% | 19 | 0 |
| Jun 30, 2024 | 21 | -9 | -30.00% | 21 | 0 |
| Dec 31, 2023 | 26 | -2 | -7.14% | 26 | 0 |
| Sep 30, 2023 | 31 | 9 | 40.91% | 31 | 0 |
| Jun 30, 2023 | 30 | 8 | 36.36% | 30 | 0 |
| Mar 31, 2023 | 28 | 9 | 47.37% | 28 | 0 |
| Dec 31, 2022 | 28 | 11 | 64.71% | 28 | 0 |
| Sep 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Jun 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Mar 31, 2022 | 19 | 7 | 58.33% | 19 | 0 |
| Dec 31, 2021 | 17 | 5 | 41.67% | 17 | 0 |
| Sep 30, 2021 | 16 | 4 | 33.33% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| PMGC Holdings | 34 |
| Lunai Bioworks | 29 |
| Imunon | 25 |
| Bolt Biotherapeutics | 23 |
| NuCana | 12 |
| Processa Pharmaceuticals | 12 |
| CDT Equity | 4 |
GNPX News
- 2 days ago - Genprex collaborators present positive preclinical data of GPX-002 in diabetes - TheFly
- 2 days ago - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - PRNewsWire
- 16 days ago - Genprex receives patent grant from The Israel Patent Office - TheFly
- 16 days ago - Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - PRNewsWire
- 18 days ago - Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - PRNewsWire
- 24 days ago - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - PRNewsWire
- 25 days ago - Genprex enters research agreement with UT MD Anderson - TheFly
- 25 days ago - Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - PRNewsWire